Sanofi has scrapped its collaboration with IGM Biosciences, eliminating the biotech’s l | Sanofi has scrapped its ...

After losing its powerhouse partner, IGM Biosciences closed “most” of its labs and offices and initiated a strategic review ...

US biotech IGM Biosciences (Nasdaq: IGMS), which is developing and delivering medicines to treat patients with autoimmune and ...

The partnership with Sanofi, which focuses on IgM-based agonists targeting autoimmune and inflammatory diseases, includes three preclinical candidates with potential milestone payments exceeding ...

Sanofi has agreed another deal to flesh out its R&D pipeline, paying IGM Biosciences $150 million upfront to gain access to its engineered IgM antibody technology across six targets in oncology ...

Cambridge, Massachusetts-based Vor Bio has confirmed that it will halt clinical and manufacturing operations, including its ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued stocks in the Pharmaceuticals industry for Tuesday, May 06, 2025. Let’s take ...

On Monday, IGM Biosciences, Inc., a pharmaceutical company based in Mountain View, California, announced the termination of a significant collaboration and license agreement with Genzyme Corporation, ...

IGM Biosciences (NASDAQ ... efforts and despite milestone payments attributed to a collaboration with Sanofi (SNY). “With no clinical assets, no clarity on strategic alternatives, and continuing ...

Functionally, rilzabrutinib suppresses anti-IgM-induced human B-cell proliferation ... under 10% serum conditions. In August 2020, Sanofi entered into a definitive agreement to acquire Principia ...